Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 38Lung Neoplasms 29Carcinoma, Non-Small-Cell Lung 28Neoplasms 16Uterine Cervical Neoplasms 13Squamous Cell Carcinoma of Head and Neck 11Esophageal Neoplasms 10Carcinoma, Hepatocellular 10Sarcoma 9Rectal Neoplasms 9Carcinoma, Renal Cell 9Prostatic Neoplasms 8Neoplasm Metastasis 8Melanoma 8Lymphoma 8Glioblastoma 8Colorectal Neoplasms 8Brain Neoplasms 8Thyroid Neoplasms 7Stomach Neoplasms 7Solid Tumor 7Pancreatic Neoplasms 7Oropharyngeal Neoplasms 7Multiple Myeloma 7Head and Neck Neoplasms 7Colonic Neoplasms 7Urinary Bladder Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Hodgkin Disease 6Breast Neoplasms, Male 6

Interventions

Trastuzumab 33pertuzumab 18Docetaxel 16pyrotinib 15Paclitaxel 7Capecitabine 6tucatinib 5Carboplatin 5Ado-Trastuzumab Emtansine 4trastuzumab deruxtecan 3neratinib 3atezolizumab 2Protons 2Neoadjuvant Therapy 2Fulvestrant 2pegfilgrastim 1palbociclib 1margetuximab 1liposomal doxorubicin 1inavolisib 1exemestane 1envafolimab 1dalpiciclib 1Taxoids 1Metformin 1Leuprolide 1Letrozole 1Isovaleryl-CoA Dehydrogenase 1Injections 1Hospital Information Systems 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Breast Cancer × Fluorodeoxyglucose F18 × Clear all
NCT04273555 2026-02-06

Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging

University of Alabama at Birmingham

Phase 1/2 Withdrawn
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡